Literature DB >> 29273641

Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis.

Ryota Niikura1, Yoku Hayakawa1, Yoshihiro Hirata1, Atsuo Yamada1, Mitsuhiro Fujishiro1,2, Kazuhiko Koike1.   

Abstract

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; gastric cancer; gastric metaplasia; proton pump inhibitor

Mesh：

Substances：

Year:  2017        PMID： 29273641     DOI： 10.1136/gutjnl-2017-315710

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  12 in total

Review 1.  Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal.

Authors:  Tahmina Nasrin Poly; Ming-Chin Lin; Shabbir Syed-Abdul; Chih-Wei Huang; Hsuan-Chia Yang; Yu-Chuan Jack Li
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

2.  Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study.

Authors:  Junya Arai; Ryota Niikura; Yoku Hayakawa; Takuya Kawahara; Tetsuro Honda; Kenkei Hasatani; Naohiro Yoshida; Tsutomu Nishida; Tetsuya Sumiyoshi; Shu Kiyotoki; Takashi Ikeya; Masahiro Arai; Nobumi Suzuki; Yosuke Tsuji; Atsuo Yamada; Takashi Kawai; Kazuhiko Koike
Journal:  Digestion       Date:  2021-12-20       Impact factor: 3.672

3.  Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.

Authors:  Peipei Liu; Úna C McMenamin; Brian T Johnston; Peter Murchie; Lisa Iversen; Amanda J Lee; Pauline A J Vissers; Chris R Cardwell
Journal:  Br J Cancer       Date:  2020-05-05       Impact factor: 7.640

4.  Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden.

Authors:  Nele Brusselaers; Jesper Lagergren
Journal:  BMJ Open       Date:  2018-07-07       Impact factor: 2.692

5.  Gastric Corpus Mucosal Hyperplasia and Neuroendocrine Cell Hyperplasia, but not Spasmolytic Polypeptide-Expressing Metaplasia, Is Prevented by a Gastrin Receptor Antagonist in H+/K+ATPase Beta Subunit Knockout Mice.

Authors:  Kristin Matre Aasarød; Helge Lyder Waldum; Astrid Kamilla Stunes; Arne Kristian Sandvik; Arnar Flatberg; Patricia Mjønes; Unni Syversen; Ingunn Bakke; Reidar Fossmark
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

Review 6.  Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility.

Authors:  Reidar Fossmark; Tom C Martinsen; Helge L Waldum
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

7.  Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis.

Authors:  Daniel Segna; Nele Brusselaers; Damian Glaus; Niklas Krupka; Benjamin Misselwitz
Journal:  Therap Adv Gastroenterol       Date:  2021-11-10       Impact factor: 4.409

Review 8.  Gastrin and the Moderate Hypergastrinemias.

Authors:  Jens F Rehfeld
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 9.  Tumor microenvironment in gastric cancers.

Authors:  Yukiko Oya; Yoku Hayakawa; Kazuhiko Koike
Journal:  Cancer Sci       Date:  2020-07-11       Impact factor: 6.716

10.  Nonsteroidal anti-inflammatory drugs prevent gastric cancer associated with the use of proton pump inhibitors after Helicobacter pylori eradication.

Authors:  Junya Arai; Ryota Niikura; Yoku Hayakawa; Hiroki Sato; Takuya Kawahara; Tetsuro Honda; Kenkei Hasatani; Naohiro Yoshida; Tsutomu Nishida; Tetsuya Sumiyoshi; Shu Kiyotoki; Takashi Ikeya; Masahiro Arai; Nobumi Suzuki; Yosuke Tsuji; Atsuo Yamada; Kazuhiko Koike
Journal:  JGH Open       Date:  2021-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.